Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Maintains $7 Price Target

Benzinga · 08/30 15:42
Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $7 price target.